Results 101 to 110 of about 16,312 (224)

Combination therapy with venlafaxine and carbamazepine in depressive patients non-responding to venlafaxine : pharmacokinetic and clinical aspects [PDF]

open access: yes, 2004
Résumé L'antidépresseur chiral venlafaxine (VEN) est à la fois un inhibiteur de la récapture de la sérotonine et de la noradrénaline. Le CYP2D6 et le CYP3A4 contribuent à son métabolisme stéreosélectif.
Ciusani, E.
core  

Tapentadol as a drug of abuse – A preliminary report

open access: yesIndian Journal of Psychiatry
Background: Tapentadol is a dual action opioid analgesic with emerging data on abuse and diversion. Aim: This study describes tapentadol abuse, clinical presentation, and treatment patterns.
Prakrithi Shivaprakash   +7 more
doaj   +1 more source

Integrated exercise program in opioid agonist therapy clinics and effect on psychological distress: study protocol for a randomized controlled trial (BAReAktiv)

open access: yesTrials
Background Substance use disorder is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. People with opioid use disorder receiving opioid agonist therapy, in particular, have high morbidity and reduced ...
Einar Furulund   +9 more
doaj   +1 more source

Poster Session 1

open access: yes
Pregnancy, Volume 2, Issue S1, January 2026.
wiley   +1 more source

Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). [PDF]

open access: yes, 2019
Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug exposure. All infants with documented in utero opioid exposure, or a high pre-test probability of exposure should have ...
Kraft, W. K.   +2 more
core   +1 more source

Buprenorphine in Neonatal Abstinence Syndrome. [PDF]

open access: yes, 2018
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and ...
Kraft, Walter K.
core   +1 more source

COVID-19 and Substance Use Disorder: Study Protocol for the International Society of Addiction Medicine Practice and Policy Interest Group Global Survey

open access: yesBasic and Clinical Neuroscience, 2020
Introduction: As one of the major health problems in the present century, the COVID-19 pandemic affected all parts of the global communities and the health of substance users are potentially at a greater risk of harm.
Alexander Baldacchino   +16 more
doaj  

REDUCTION OF DAMAGE AS A STRATEGY FOR THE USE AND ABUSE OF SUBSTANCES IN MEXICO: CHALLENGES AND OPPORTUNITIES

open access: yesRa Ximhai, 2017
Harm reduction is suggested as a paradigm shift in addressing problematic drug use, the goal of the model is to lessen the consequences of dependence.
Arodi Tizoc-Marquez   +3 more
doaj  

Improving hospital-based opioid substitution therapy (iHOST): protocol for a mixed-methods evaluation [version 2; peer review: 2 approved]

open access: yesNIHR Open Research
Background Opioid substitution therapy (also known as ‘opioid agonist therapy’ or ‘medication treatment of opioid use disorder’) is associated with improved health and social outcomes for people who use heroin and other illicit opioids.
Marisha Wickremsinhe   +17 more
doaj   +1 more source

Emergence of opiate substitution treatment in general practice

open access: yes, 2010
In the nineteen nineties, the drug addiction treatment world took a change of direction. Until then "drug addiction" was confined to specialised approach, which treated it as the symptom of a disturbance inherent in the individual, psychological in origin.
openaire   +1 more source

Home - About - Disclaimer - Privacy